---
title: Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell
  therapy for secondary neurolymphomatosis
date: '2024-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39440883/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241023210141&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Lymphomatous infiltration of the peripheral nervous system (PNS), termed
  neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant
  with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy
  has emerged as a safe and effective treatment for B-cell lymphomas. We aimed to
  assess toxicity and efficacy of CD19-CAR T-cells in neurolymphomatosis. Neurolymphomatosis
  patients treated with CD19 CAR T-cells were retrospectively identified at ...
disable_comments: true
---
Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as a safe and effective treatment for B-cell lymphomas. We aimed to assess toxicity and efficacy of CD19-CAR T-cells in neurolymphomatosis. Neurolymphomatosis patients treated with CD19 CAR T-cells were retrospectively identified at ...